Pfizer Scraps Daily Weight Loss Pill After Liver Injury | Vantage with Palki Sharma | N18G

Pfizer Scraps Daily Weight Loss Pill After Liver Injury | Vantage with Palki Sharma | N18G

Pfizer has halted development of its potential weight loss pill after a patient suffered liver injury during a trial. The weight loss drug market is projected to hit $150 billion by the early 2030s, with drugs like Ozempic and Wegovy growing in popularity. But concerns about the risks of weight loss drugs remain. How safe are weight loss drugs? How much do we know about them?

---

Pfizer | Weight-Loss Drug | Ozempic | Wegovy | Health | Side Effects | Tirzepatide | Eli Lilly | Mounjaro | Zepbound | Firstpost | World News | Vantage | Palki Sharma

#pfizer #weightlossdrug #tirzepatide #firstpost #vantageonfirstpost #palkisharma #worldnews

Vantage is a ground-breaking news, opinions, and current affairs show from Firstpost. Catering to a global audience, Vantage covers the biggest news stories from a 360-degree perspective, giving viewers a chance to assess the impact of world events through a uniquely Indian lens.

The show is anchored by Palki Sharma, Managing Editor, Firstpost.

By breaking stereotypes, Vantage aims to challenge conventional wisdom and present an alternative view on global affairs, defying the norm and opening the door to new perspectives. The show goes beyond the headlines to uncover the hidden stories – making Vantage a destination for thought-provoking ideas.

Vantage airs Monday to Friday at 9 PM IST on Firstpost across all leading platforms.
​
Subscribe to Firstpost channel and press the bell icon to get notified when we go live.
   / @firstpost  

Follow Firstpost on Instagram:
  / firstpost  

Follow Firstpost on Facebook:
  / firstpostin  

Follow Firstpost on Twitter:
  / firstpost  

Follow Firstpost on WhatsApp:
https://www.whatsapp.com/channel/0029...